Cover Image
市場調查報告書

全球癌症治療藥產業、市場:企業、治療藥、R&D、預測 2015-2025年

World Cancer-Treating Drugs Industry and Market: Companies, Therapies, R&D and Forecasts 2015-2025

出版商 Visiongain Ltd 商品編碼 336177
出版日期 內容資訊 英文 273 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
全球癌症治療藥產業、市場:企業、治療藥、R&D、預測 2015-2025年 World Cancer-Treating Drugs Industry and Market: Companies, Therapies, R&D and Forecasts 2015-2025
出版日期: 2015年07月23日 內容資訊: 英文 273 Pages
簡介

全球癌症治療藥市場,預計2019年將產生1,249億美元的收益。預計到2025年穩定地擴大收益。

本報告提供全球癌症治療藥市場相關調查、全球市場規模、4個次市場上收益的預測、各國市場預測、各癌症類型的R&D,及主要8家公司簡介等彙整資料。

第1章 調查概要

第2章 癌症治療的簡介

  • 癌症的生理學:原因、影響
  • 癌症的發病率、普及率:全球趨勢
  • 腫瘤的治療:怎樣反擊?

第3章 全球抗癌藥市場

  • 全球抗癌藥市場預測
  • 免疫療法具支配性
  • 免疫療法的抗癌藥市場預測
  • 化療的抗癌藥市場預測
  • 標靶治療的抗癌藥市場預測
  • 荷爾蒙療法的抗癌藥市場預測

第4章 主要國家市場

  • 抗癌藥:主要市場
  • 美國的抗癌藥市場
  • 日本的抗癌藥市場
  • 歐盟5國的抗癌藥市場
  • 金磚四國的抗癌藥市場

第5章 前25大抗癌藥:收益預測

  • Avastin (Roche)
  • Herceptin (Roche)
  • Rituxan/MabThera (Roche)
  • Gleevec/Glivec (Novartis)
  • Revlimid (Celgene)
  • Alimta (Eli Lilly)
  • Velcade (J&J/武田藥品工業)
  • Erbitux (Bristol-Myers Squibb/Merck KGaA)
  • Gardasil (Merck & Co.)
  • Zytiga (Johnson & Johnson)
  • Xeloda (Roche)
  • Tarceva (Roche)
  • Afinitor (Novartis)
  • Sprycel (Bristol-Myers Squibb)
  • Tasigna (Novartis)
  • Sutent (Pfizer)
  • Nexavar (Bayer/Onyx Pharmaceuticals)
  • Xgeva (Amgen)
  • Zoladex (AstraZeneca)
  • Yervoy (Bristol-Myers Squibb)
  • Vidaza (Celgene)
  • Treanda (Teva Pharmaceuticals)
  • Temodar/ Temodal(Merck & Co.)
  • Faslodex (AstraZeneca)
  • Abraxane (Celgene)

第6章 認證藥:未來的暢銷藥的可能性

第7章 癌症治療藥的主要企業

  • 抗癌藥市場由7家公司壟斷
  • Roche
  • Novartis
  • Celgene
  • Eli Lilly
  • AstraZeneca
  • Bristol-Myers Squibb
  • Merck &Co.
  • Johnson & Johnson

第8章 癌症治療的研發產品線

  • 開發中的乳癌治療藥
  • 開發中的前列腺癌治療藥
  • 開發中的肺癌治療藥
  • 開發中的大腸癌症治療藥
  • 開發中的子宮頸癌治療藥
  • 開發中的胃癌治療藥
  • 開發中的肝癌治療藥
  • 開發中的卵巢癌治療藥
  • 開發中的膀胱癌治療藥
  • 開發中的非何杰金氏淋巴瘤治療藥
  • 開發中的白血病治療藥
  • 開發中的肝癌治療藥
  • 開發中的胰臟癌治療藥

第9章 抗癌藥市場定性分析

  • SWOT分析
  • STEP分析

第10章 調查採訪

第11章 結論

  • 癌症治療藥市場的前25大
  • 免疫療法:市場的未來
  • 專利到期、生技仿製藥的影響
  • 美國:依然是最大的國別市場
  • 中國、巴西領導新興市場
  • 治療:個人用
  • 抗癌藥開發平台維持強力
  • 結論

圖表清單

目錄
Product Code: PHA0056

Cancer Treatments - Your New Guide to that Market, its R&D and Sales Potentials

Do you want to assess the future of cancer-treating medicines? Visiongain's new report gives you revenue predictions for that industry from 2015, helping you stay ahead. There you discover financial data, R&D trends, opportunities, interviews and revenue forecasts.

In our analysis you see forecasted sales to 2025 at overall world market, submarket, product and national level. You assess emerging trends, technologies and branded therapies. With our study, benefit your research, analysis, decisions, presentations and influence.

Events shaping that crucial pharma industry - cancer remains a top priority for healthcare

Discover in our work what the future holds for cancer medicines. Those treatments become ever more important to pharmaceutical companies. Discover why, seeing what shapes that industry. Explore prospects from 2015 for that technology and business.

That way you assess how patients, treatment providers and drug producers stand to benefit from 2015 to 2025. Our study predicts high, rising spending on cancer-treating products. Stay ahead, then, in knowledge to benefit your work.

Please read on now to examine the anti-cancer drugs industry. Also see, below, how high that market's future revenues could go.

Forecasts from 2015 and other analyses show you therapies' sales potentials

Is finding data for cancer treatment a challenge? Reduce time spent getting information. Our work shows the most promising and lucrative parts of applied oncology.

Besides revenue forecasting to 2025, our study reveals historical data, growth rates and market shares. You assess quantitative and qualitative analyses, commercial news, outlooks and developments (R&D). In addition, you gain 122 tables, 137 charts and two interviews.

Avoid missing out. The purpose of our analysis is to help you stay ahead in knowledge and benefit your authority on the potential of cancer-treating drugs.

Many opportunities remain for those treatments. Now see how you can benefit your research, analyses and decisions on those medicines, including biological drugs (biologics).

The following sections show how our new investigation helps your work. Discover there how you could benefit your reputation for technological and commercial insight.

Outlooks for the world cancer drugs market and segments - what sales are possible?

Along with prediction of overall world market value to 2025, our report shows you individual revenue forecasting of four therapeutic submarkets at world level:

  • Immunotherapy
  • Chemotherapy
  • Targeted treatments
  • Hormone-based therapy.

Our study also discusses what stimulates and restrains business. That analysis helps you identify potential and find ways for your company to develop. You assess leading brands too.

Forecasts for 25 leading drugs and 15 emerging medicines - discover selling potentials

How will leading drugs perform to 2025 at world level? Our study predicts individual revenues of the top 25 anti-cancer agents from 2015, including these products:

  • Avastin
  • Herceptin
  • Rituxan/MabThera
  • Gleevec/Glivec
  • Revlimid
  • Alimta
  • Velcade
  • Erbitux.

You also discover individual selling potentials of 15 emerging therapies, recently approved, including these agents:

  • Farydak
  • Ibrance
  • Lenvima
  • Opdivo
  • Unituxin
  • Beleodaq
  • Cyramza
  • Imbruvica.

There, in our analyses, you see how high sales can go, to 2025, finding drugs and years with highest predicted growth and revenues. You examine what's happening, understanding trends, competition, challenges and opportunities. That information helps you compete.

Our new survey also shows geographical revenue predictions, a breakdown of our overall world market forecast.

Leading national markets - where can highest revenues and growth occur?

Developments worldwide expand the cancer drugs market, especially rising demand for medicines in emerging countries. China, India, Russia and Brazil underpin revenue growth.

In developed and developing countries, opportunities for pharma companies will occur from 2015. Our study shows you the most promising countries for revenues and sales growth.

There you gain individual revenue forecasts to 2025 for 11 national markets:

  • United States (US)
  • Japan
  • Germany, France, United Kingdom (UK), Italy and Spain (the EU5 group)
  • Brazil, Russia, India and China (BRIC nations).

Our analyses show sales growth will occur in established pharma markets and in developing countries. In particular, drug launches from 2015 to 2025 will change medical prescribing and the commercial landscape.

Discover, too, where R&D in oncology heads.

Research and development - assess innovation, trends and possibilities

What's happening in oncological R&D? Our study reveals and explains trends for treating cancers. That way you explore drug development in these fields of oncology, by cancer type:

  • Breast
  • Prostate
  • Lung
  • Intestinal
  • Cervix
  • Stomach
  • Liver.

Our work also discusses products in development for these cancers, including progress in clinical trials:

  • Ovary
  • Bladder
  • Kidney
  • Pancreas
  • Non-Hodgkin's lymphoma
  • Leukaemia.

R&D in oncology holds strength, variety and promise. You assess innovations for treating those diseases, hearing about developments and finding their significance. Our study shows you what's possible to benefit patients, healthcare providers and pharmaceutical companies.

For large firms and specialty pharma there exist many opportunities. Our study explains, discussing issues to help your work. Examine changes shaping that market from 2015.

Forces changing the industry and market for cancer-treating medicines

Our new report discusses issues and events from 2015 that affect companies in the market, including these influences:

  • Rising incidence of cancers - increasing demand for existing and new anti-cancer medicines
  • Monoclonal antibodies (mAbs), cancer vaccines and non-specific immunotherapies
  • Targeted therapies and differentiating agents
  • Challenges and opportunities of drug development - outlooks for the future.

Our survey discusses other aspects of cancer treatment, including these trends:

  • Patent expiries and the impact of generics and biosimilars - rising competition, including the need for technological advances to help innovators stay ahead
  • Extension of approved uses - the quest for new indications, further clinical testing
  • Shifts towards personalised medicine - the applications of biomedical technologies
  • Point-of-care and real time testing of tumours - advances in diagnostic tests.

With that analysis you explore technological, economic, social and political questions, assessing outlooks for developers, manufacturers and sellers. You also assess the cancer drug industry's strengths, weaknesses, opportunities and threats.

See what's possible for companies in that industry. What does their future hold?

Leading companies and 2019 market value

From 2015, new treatments hold great potential for investment, technological advances and high sales. Our analyses predict the world cancer drugs market will reach $124.9bn in 2019. Visiongain forecasts strong revenue expansion to 2025, with pharma companies benefiting.

Our analysis shows you what technologies, products and organisations hold greatest potential. That way you explore leading companies and their outlooks, including these firms:

  • Roche
  • Novartis
  • Celgene
  • Eli Lilly
  • AstraZeneca
  • Bristol-Myers Squibb
  • Johnson & Johnson
  • Merck & Co.

Prospects for R&D and sales in oncology are strong, and from 2015 there will arise many opportunities. See where. Our report shows you the possibilities, helping you succeed.

Seven ways World Cancer-Treating Drugs Industry and Market: Companies, Therapies, R&D and Forecasts 2015-2025 helps

In these seven main ways, our new analysis gives knowledge to make your work easier and faster, also benefiting your decisions:

  • World market size to 2025 and revenues for 4 submarkets - assess outlooks for development, production, marketing and sales, seeing what's possible
  • 25 leading drugs' and 15 emerging medicines' revenues to 2025 - find sales potentials for top brands, seeing how they can compete and succeed
  • 11 national markets' forecasts to 2025 - investigate leading countries in the Americas, Europe and Asia for revenues and market expansion
  • R&D by cancer type - explore progress in research and development, finding technological and medical possibilities, seeing potential new products
  • Profiles of 8 companies - analyse leading participants' results, portfolios, capabilities, deals and outlooks
  • Interviews with two other authorities - discover opinions to help you stay ahead
  • Analysis of what stimulates and restrains the cancer treatments sector - assess challenges and opportunities, helping you gain advantages and succeed.

Knowledge found nowhere else, benefiting your influence in pharma biotechnology

Our work gives independent analysis. There you gain competitive intelligence found only in that report. You see where business prospects are most rewarding and promising.

That new report, by visiongain's UK-based in-house analysts, gives knowledge to benefit your research, analyses, plans, decisions and proposals. You get data leading companies depend on.

With our investigation you are less likely to fall behind in data or miss opportunity. Discover there, by your choice, how to save time and benefit your information searches. Also see how our analysis could benefit your reputation for technological and commercial insight.

Trying our report now lets you discover biopharma opportunities and forecasts

Our new report's purpose is to help professionals analysing cancer treatments. See what's possible for developers, producers and marketers. You find trends, opportunities and revenue predictions. So avoid missing out - please get that study here now.

Visiongain is a trading partner with the US Federal Government.

Table of Contents

1. Report Overview

  • 1.1. Overview of the World Market for Cancer-Treating Drugs
  • 1.2. Why You Should Read This Report
  • 1.3. How This Study Delivers
  • 1.4. Main Questions Answered by this Analysis
  • 1.5. Who is this Report For?
  • 1.6. Methods of Research and Analysis
  • 1.7. Frequently Asked Questions(FAQs)
  • 1.8. Some Associated Reports
  • 1.9. About Visiongain

2. Introduction to Cancer Treatments

  • 2.1. The Physiology of Cancer - Causes and Effects
    • 2.1.1. Uncontrolled Growth
    • 2.1.2. Dedifferentiation
    • 2.1.3. Invasiveness and Metastasis
    • 2.1.4. Causes of Cancer
  • 2.2. The Incidence and Prevalence of Cancer - Trends in the World
    • 2.2.1. Incidence
    • 2.2.2. Mortality
    • 2.2.3. Survival - Improving Odds
      • 2.2.3.1. The Developed World
      • 2.2.3.2. The Developing World - More Must Be Done
  • 2.3. Treating Tumours - How Can We Fight Back?
    • 2.3.1. Chemotherapy - The Traditional Treatment
    • 2.3.2. Hormone Therapies
    • 2.3.3. Immunotherapy - A Magic Bullet?
      • 2.3.3.1. Monoclonal Antibodies(mAbs)
      • 2.3.3.2. Cancer Vaccines
      • 2.3.3.3. Non-Specific Immunotherapies
    • 2.3.4. Targeted Therapies
    • 2.3.5. Differentiating Agents

3. The World Anti-Cancer Drugs Market, 2015-2025

  • 3.1. Global Anti-Cancer Drugs Market Forecast, 2015-2025
  • 3.2. The Domination of Immunotherapies in 2014
  • 3.3. The Immunotherapy Anti-Cancer Drugs Market Forecast, 2015-2025 - The Fastest Growing Segment
  • 3.4. The Chemotherapy Anti-Cancer Drugs Market Forecast, 2015-2025
  • 3.5. The Targeted Therapy Anti-Cancer Drugs Market Forecast, 2015-2025 - A Move towards Personalisation
  • 3.6. The Hormone Therapy Anti-Cancer Drugs Market Forecast, 2015-2025

4. Leading National Markets, 2015-2025

  • 4.1. Anti-Cancer Drugs - Leading Markets, 2014
  • 4.2. The US Anti-Cancer Drugs Market, 2015-2025 - Continued Leadership or Terminal Decline?
    • 4.2.1. The US Anti-Cancer Drugs Market, 2014
    • 4.2.2. The US Anti-Cancer Drugs Market Forecast - A Matured Approach
    • 4.2.3. The Effect of Regulations on the US Market
  • 4.3. The Japanese Anti-Cancer Drugs Market, 2015-2025 - Still Steady?
  • 4.4. The EU5 Anti-Cancer Drugs Market, 2015-2025 - Rivalling the US in Importance
  • 4.5. The BRIC Countries Anti-Cancer Drugs Market, 2015-2025 - Awakening Sleeping Giants?
    • 4.5.1. The Brazilian Anti-Cancer Drugs Market, 2015-2025 - Expansion of the Middle Class
    • 4.5.2. The Russian Anti-Cancer Drugs Market, 2015-2025 - Rising Cancer Rates Stimulate Revenue Increases
    • 4.5.3. The Indian Anti-Cancer Drugs Market, 2015-2025 - Lucrative Opportunity for Growth
    • 4.5.4. The Chinese Anti-Cancer Drugs Market, 2015-2025 - Can it Reach its Potential?

5. The Top 25 Anti-Cancer Drugs: Revenue Forecasts, 2015-2025

  • 5.1. Avastin(Roche) - The World Market Leader
    • 5.1.1. Avastin Revenue, 2011-2014 - Mixed Growth
    • 5.1.2. Avastin Revenue Forecast - Still No.1?
  • 5.2. Herceptin(Roche) - The Looming Impact of Patent Expiry
    • 5.2.1. Herceptin Revenue, 2011-2014 - Still Rising
    • 5.2.2. Herceptin Revenue Forecast - Generic Erosion
  • 5.3. Rituxan/MabThera(Roche) - Slowing Growth
    • 5.3.1. Rituxan Revenue, 2011-2014 - Still Strong
    • 5.3.2. Rituxan Revenue Forecast - Heading for a Decline
  • 5.4. Gleevec/Glivec(Novartis) - The Maturation of a Blockbuster
    • 5.4.1. Glivec Revenue, 2011-2014
    • 5.4.2. Glivec Revenue Forecast - What Does the Future Hold?
  • 5.5. Revlimid(Celgene) - Celgene's Top Revenue Generator
    • 5.5.1. Revlimid Revenue, 2011-2014 - Still on the Rise
    • 5.5.2. Revlimid Revenue Forecast - A Long Term Leader?
  • 5.6. Alimta(Eli Lilly) - A Slow Decline?
    • 5.6.1. Alimta Revenue, 2011-2014
    • 5.6.2. Alimta Revenue Forecast - Revenue Erosion Looming
  • 5.7. Velcade(J&J/Takeda) - Rising Steadily
    • 5.7.1. Velcade Revenue, 2011-2014
    • 5.7.2. Velcade Revenue Forecast - A Dependable Sales Generator
  • 5.8. Erbitux(Bristol-Myers Squibb/Merck KGaA) - Facing Tough Competition
    • 5.8.1. Erbitux Revenue, 2011-2014
    • 5.8.2. Erbitux Revenue Forecast - No More Growth?
  • 5.9. Gardasil(Merck & Co.) - The Rise of Prevention
    • 5.9.1. Gardasil Revenue, 2011-2014
    • 5.9.2. Gardasil Revenue Forecast - Still Growing Strong
  • 5.10. Zytiga(Johnson & Johnson)
    • 5.10.1. Zytiga Revenue, 2011-2014 - The Rise of a New Drug
    • 5.10.2. Zytiga Revenue Forecast
  • 5.11. Xeloda(Roche) - Patent Exclusivity and the Future
    • 5.11.1. Xeloda Revenue, 2011-2014 - The Impact of Combination Therapies
    • 5.11.2. Xeloda Revenue Forecast - A Slippery Slope
  • 5.12. Tarceva(Roche)
    • 5.12.1. Tarceva Revenue, 2011-2014 - No Clear Pattern
    • 5.12.2. Tarceva Revenue Forecast
  • 5.13. Afinitor(Novartis) - A Targeted Approach
    • 5.13.1. Afinitor Revenue, 2011-2014 - Growing Fast
    • 5.13.2. Afinitor Revenue Forecast
  • 5.14. Sprycel(Bristol-Myers Squibb)
    • 5.14.1. Sprycel Revenue, 2011-2014
    • 5.14.2. Sprycel Revenue Forecast - How Long Will the Growth Last?
  • 5.15. Tasigna(Novartis) - Moving Up
    • 5.15.1. Tasigna Revenue, 2011-2014
    • 5.15.2. Tasigna Revenue Forecast - A Multi-Billion Dollar Product?
  • 5.16. Sutent(Pfizer)
    • 5.16.1. Sutent Revenue, 2011-2014
    • 5.16.2. Sutent Revenue Forecast - No More Growth
  • 5.17. Nexavar(Bayer/Onyx Pharmaceuticals)
    • 5.17.1. Nexavar Revenue, 2011-2014 - The Effect of Regional Sales
    • 5.17.2. Nexavar Revenue Forecast - A Promising Start
  • 5.18. Xgeva(Amgen)
    • 5.18.1. Xgeva Revenue, 2011-2014 - The Impact of New Indications
    • 5.18.2. Xgeva Revenue Forecast
  • 5.19. Zoladex(AstraZeneca)
    • 5.19.1. Zoladex Revenue, 2011-2014
    • 5.19.2. Zoladex Revenue Forecast
  • 5.20. Yervoy(Bristol-Myers Squibb) - Starting to Make its Mark
    • 5.20.1. Yervoy Revenue, 2011-2014
    • 5.20.2. Yervoy Revenue Forecast - Will Sales Keep Growing?
  • 5.21. Vidaza(Celgene) - What Growth Potential?
    • 5.21.1. Vidaza Revenue, 2011-2014
    • 5.21.2. Vidaza Revenue Forecast - Generic Impact?
  • 5.22. Treanda(Teva Pharmaceuticals)
    • 5.22.1. Treanda Revenue, 2011-2014
    • 5.22.2. Treanda Revenue Forecast - Stalled Growth?
  • 5.23. Temodar/Temodal(Merck & Co.) - Falling off the Cliff?
    • 5.23.1. Temodar/Temodal Revenue, 2011-2014
    • 5.23.2. Temodar/Temodal Revenue Forecast
  • 5.24. Faslodex(AstraZeneca) - The Counterpart to Zoladex
    • 5.24.1. Faslodex Revenue, 2011-2014
    • 5.24.2. Faslodex Revenue Forecast
  • 5.25. Abraxane(Celgene) - Beginning the Climb
    • 5.25.1. Abraxane Revenue, 2011-2014
    • 5.25.2. Abraxane Revenue Forecast

6. Drugs Approved in 2014-2015: Potential Future Blockbusters

  • 6.1. Approved Treatments in 2015
    • 6.1.1. Farydak(panobinostat/Novartis)
    • 6.1.2. Ibrance(palbociclib/Pfizer)
    • 6.1.3. Lenvima(lenvatinib mesylate/Eisai)
    • 6.1.4. Opdivo(nivolumab/Bristol-Myers Squibb)
    • 6.1.5. Unituxin(dinutuximab/United Therapeutics)
  • 6.2. Approved Treatments in 2014
    • 6.2.1. Beleodaq(belinostat/Spectrum Pharmaceuticals)
    • 6.2.2. Blincyto(blinatumomab/Amgen)
    • 6.2.3. Cyramza(ramucirumab/Eli Lilly): A Breakthrough for Gastric Cancer?
    • 6.2.4. Imbruvica(ibrutinib/Pharmacyclics)
    • 6.2.5. Keytruda(pembrolizumab/Merck)
    • 6.2.6. Lynparza(olaparib/AstraZeneca)
    • 6.2.7. Zydelig(idelalisib/Gilead)
    • 6.2.8. Zykadia(ceritinib/Novartis) - The Rise of Kinase Inhibitors
    • 6.2.9. Tafinlar(Novartis) - A Partner for Mekinist
    • 6.2.10. Kadycla(Roche) - A Future Star

7. Leading Companies for Cancer Treatments, 2014

  • 7.1. Anti-Cancer Drug Market Dominated by Seven Companies
  • 7.2. Roche - Leader of the Pack
    • 7.2.1. Oncology Pipeline - Investment in the Future
    • 7.2.2. Roche's Future Direction in Cancer Treatment
  • 7.3. Novartis - Closing the Gap on Roche
    • 7.3.1. Oncology R&D Pipeline - What's the Potential?
    • 7.3.2. Future Directions for Novartis
  • 7.4. Celgene - A Pressing Need to Diversify?
    • 7.4.1. Celgene's Oncology R&D Pipeline - Safeguarding the Future
    • 7.4.2. Future Directions for Celgene
  • 7.5. Eli Lilly - Reliant on Alimta
    • 7.5.1. Oncology R&D Pipeline - What Potential Exists?
    • 7.5.2. The Future Direction of Eli Lilly
  • 7.6. AstraZeneca - Climbing Up the Ladder
    • 7.6.1. Oncology R&D Pipeline - Showing Promise
    • 7.6.2. The Future Direction of AstraZeneca
  • 7.7. Bristol-Myers Squibb
    • 7.7.1. Oncology R&D Pipeline - What Potential Exists?
    • 7.7.2. Future Direction of BMS
  • 7.8. Merck &Co. - Prominent in Vaccines
    • 7.8.1. Oncology R&D Pipeline - Greater Focus on Cancer
    • 7.8.2. The Future Direction of Merck
  • 7.9. Johnson & Johnson
    • 7.9.1. Oncology J&J Pipeline - A Focus on Prostate Cancer Drugs

8. R&D Pipelines for Cancer Treatment

  • 8.1. Breast Cancer Drugs under Development
    • 8.1.1. Neratinib(Puma Pharmaceuticals)
    • 8.1.2. Veliparib(Abbvie)
    • 8.1.3. NeuVax(Galena Biopharma)
    • 8.1.4. Entinostat(Syndax)
  • 8.2. Prostate Cancer Drugs under Development
    • 8.2.1. ODM-201(Orion) - Jointly Developed with Bayer
    • 8.2.2. Tasquinimod(Active Biotech)
    • 8.2.3. EMD-525797(EMD Serono)
    • 8.2.4. PROSTVAC(Bavarian Nordic)
  • 8.3. Lung Cancer Drugs under Development
    • 8.3.1. RG7446(Roche)
    • 8.3.2. Nivolumab(Bristol-Myers Squibb)
    • 8.3.3. MEDI4736(AstraZeneca)
    • 8.3.4. TG4010(Transgene)
  • 8.4. Colorectal Cancer Drugs under Development
    • 8.4.1. Imprime PGG(Biothera)
    • 8.4.2. Xilonix(Xbiotech)
    • 8.4.3. HA-Irinotecan(Alchemia)
  • 8.5. Cervical Cancer Drugs under Development
    • 8.5.1. ADXS-HPV(Advaxis)
    • 8.5.2. V503(Merck & Co.)
    • 8.5.3. VGX-3100(Inovio Pharmaceuticals)
  • 8.6. Stomach Cancer Drugs under Development
    • 8.6.1. Rilotumumab(Amgen)
    • 8.6.2. Onartuzumab(Roche)
    • 8.6.3. Apatinib(Jiangsu Hengrui Medicine)
  • 8.7. Liver Cancer Drugs under Development
    • 8.7.1. Tivantinib(ArQule)
    • 8.7.2. Lenvatinib(Eisai Co.)
    • 8.7.3. Pexa-Vec(Jennerex Biotherapeutics)
    • 8.7.4. Brivanib(Bristol-Myers Squibb)
    • 8.7.5. Muparfostat(Progen Pharmaceuticals)
  • 8.8. Ovarian Cancer Drugs under Development
    • 8.8.1. Farletuzumab(Eisai)
    • 8.8.2. Niraparib(TESARO)
    • 8.8.3. Trebananib(Amgen)
  • 8.9. Bladder Cancer Drugs under Development
    • 8.9.1. Vesimune(Telormedix)
    • 8.9.2. HS-410(Heat Biologics)
    • 8.9.3. EOquin(Allergan)
  • 8.10. Non-Hodgkin's Lymphoma Drugs under Development
    • 8.10.1. Idelalisib(Gilead)
    • 8.10.2. IPI-145(Infinity Pharmaceuticals)
    • 8.10.3. ABT-199(AbbVie)
    • 8.10.4. GS-9973(Gilead)
  • 8.11. Leukaemia Drugs under Development
    • 8.11.1. Dinaciclib(Merck)
    • 8.11.2. Sapacitabine(Cyclacel Pharmaceuticals)
    • 8.11.3. Vosaroxin(Sunesis)
  • 8.12. Kidney Cancer Drugs under Development
    • 8.12.1. IMA901(Immatics)
    • 8.12.2. AGS-003(Argos Therapeutics)
    • 8.12.3. Nilovumab(Bristol-Myers Squibb)
    • 8.12.4. TRC105(Tracon Pharmaceuticals)
  • 8.13. Pancreatic Cancer Drugs under Development
    • 8.13.1. Algenpantucel-L(NewLink Genetics)
    • 8.13.2. MM-398(Merrimack)
    • 8.13.3. MK-0752(Merck & Co.)

9. Qualitative Analysis of the Anti-Cancer Drug Market 2015-2025

  • 9.1. SWOT Analysis of the Anti-Cancer Drugs Market
    • 9.1.1. Strengths of the Market
      • 9.1.1.1. The Rising Incidence of Cancer
      • 9.1.1.2. Ample Treatment Options Available
    • 9.1.2. Weaknesses
      • 9.1.2.1. The Challenges of Drug Development
      • 9.1.2.2. The Complex Nature of Cancer
    • 9.1.3. Opportunities in the Anti-Cancer Drugs Market
      • 9.1.3.1. The Advancement of Research
      • 9.1.3.2. A Shift Towards Personalisation
    • 9.1.4. Threats Facing the Anti-Cancer Drugs Market
      • 9.1.4.1. The Threat of Regulation
  • 9.2. STEP Analysis of the Anti-Cancer Drugs Market
    • 9.2.1. Social Factors: The Cost of Living Longer
    • 9.2.2. Technological Developments: Making the Market Move Forward
    • 9.2.3. Economic Pressure: Treatment's Hefty Price Tag
    • 9.2.4. Political Issues: Governmental Involvement in Treatment

10. Research Interviews from Our Survey

  • 10.1. Dr Cesar M. Castro, Massachusetts General Hospital Cancer Center and Center for Systems Biology, Boston
    • 10.1.1. D3 Enables Point-of-care and Real Time Testing of Tumours
    • 10.1.2. The Use of D3 to Detect Cancer
    • 10.1.3. D3 - Speed, Ease of Use, Low Cost and Accurate
    • 10.1.4. D3 - Possibility of Detecting Various Types of Cancer
    • 10.1.5. Further Development and Refinement
  • 10.2. Dr Silvia Paddock, Senior Associate, Rose Li and Associates, Inc.
    • 10.2.1. PACE CII - Meeting the Needs of a Diverse Range of Stakeholders
    • 10.2.2. PACE CII - Main Components
    • 10.2.3. PACE CII - a Flexible Framework for Objective Assessments of Progress
    • 10.2.4. Value of Cancer Treatments - Dynamic and Complex
    • 10.2.5. Multiple Stakeholders - Shared Perspectives on Treatment Goals?
    • 10.2.6. Free Access to Database and Tool

11. Conclusions of the Study

  • 11.1. The Top 25 Drugs in the Cancer Treatment Market
  • 11.2. Immunotherapies - The Future of the Market
  • 11.3. Patent Expiries and the Impact of Biosimilars
  • 11.4. The US - Still the Largest National Market
  • 11.5. China and Brazil Will Lead the Emerging Markets
  • 11.6. Treatment - It's Personal
  • 11.7. The Anti-Cancer Drug Pipeline Remains Strong
  • 11.8. Concluding Remarks

List of Tables

  • Table 1.1: Forecast Regional and National Anti-Cancer Drugs Markets: Market Sizes ($bn), Annual Growth (%), CAGRs (%), 2014-2019
  • Table 1.2: Forecast Regional and National Anti-Cancer Drugs Markets: Market Sizes ($bn), Annual Growth (%), CAGRs (%), 2019-2025
  • Table 2.1: Cancer-Treating Agents: Chemotherapies and Hormone Therapies, 2014
  • Table 2.2: Cancer-Treating Agents: Immunotherapies, Targeted Therapies and Differentiating Agents, 2014
  • Table 3.1: The Global Anti-Cancer Drugs Market: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
  • Table 3.2: Global Anti-Cancer Drugs Market by Therapeutic Area: Revenue ($bn) and Market Share (%), 2013-2014
  • Table 3.3: Global Anti-Cancer Drugs Market by Therapeutic Area: Revenue Forecast ($bn), CAGR (%) and Market Share (%), 2014, 2019 and 2025
  • Table 3.4: Global Immunotherapy Market: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
  • Table 3.5: Global Chemotherapy Market: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
  • Table 3.6: Global Targeted Therapy Market: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
  • Table 3.7: Global Hormone Therapy Market: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
  • Table 4.1: Anti-Cancer Drugs Market Revenue ($bn) and Market Share (%) by Leading Country, 2014, 2019, 2025
  • Table 4.2: Leading National Anti-Cancer Drugs Markets: Revenue Forecasts ($bn), Annual Growth (%), CAGR (%) and Market Share (%), 2015-2025
  • Table 4.3: The US Anti-Cancer Drugs Market Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
  • Table 4.4: The Japanese Anti-Cancer Drugs Market Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
  • Table 4.5: EU5 Anti-Cancer Drugs Market Revenue Forecasts ($bn), Annual Growth (%) and CAGR (%), 2015-2025
  • Table 4.6: The BRIC Countries Anti-Cancer Drugs Market: Revenue Forecasts ($bn), Annual Growth (%) and CAGR (%), 2015-2025
  • Table 4.7: Brazilian Anti-Cancer Drugs Market: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
  • Table 4.8: Russian Anti-Cancer Drugs Market: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
  • Table 4.9: Indian Anti-Cancer Drugs Market: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
  • Table 4.10: Chinese Anti-Cancer Drugs Market: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
  • Table 5.1: Top 25 Anti-Cancer Drugs: Revenue ($bn) and Market Share (%), 2014
  • Table 5.2: Top 10 Anti-Cancer Drugs: Revenue Forecasts ($bn), CAGR (%) and Market Share (%), 2014, 2019, 2025
  • Table 5.3: Top 25 Anti-Cancer Drugs: Revenue Forecasts ($bn), 2015-2025
  • Table 5.4: Top 25 Anti-Cancer Drugs: Revenue Forecasts ($bn), 2015-2025 (Contd.)
  • Table 5.5: Top 25 Anti-Cancer Drugs: Revenue Forecasts ($bn), 2015-2025 (Contd.)
  • Table 5.6: Avastin Revenue ($bn), Annual Growth (%) and CAGR (%), 2011-2014
  • Table 5.7: Avastin Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
  • Table 5.8: Herceptin Revenue ($bn), Annual Growth (%) and CAGR (%), 2011-2014
  • Table 5.9: Herceptin Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
  • Table 5.10: Rituxan/MabThera Revenue ($bn), Annual Growth (%) and CAGR (%), 2011-2014
  • Table 5.11: Rituxan/MabThera Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
  • Table 5.12: Glivec Revenue ($bn), Annual Growth (%) and CAGR (%), 2011-2014
  • Table 5.13: Glivec Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
  • Table 5.14: Revlimid Revenue ($bn), Annual Growth (%) and CAGR (%), 2011-2014
  • Table 5.15: Revlimid Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
  • Table 5.16: Alimta Revenue ($bn), Annual Growth (%) and CAGR (%), 2011-2014
  • Table 5.17: Alimta Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
  • Table 5.18: Velcade Revenue ($bn), Annual Growth (%) and CAGR (%), 2011-2014
  • Table 5.19: Velcade Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
  • Table 5.20: Erbitux Revenue ($bn), Annual Growth (%) and CAGR (%), 2011-2014
  • Table 5.21: Erbitux Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
  • Table 5.22: Gardasil Revenue ($bn), Annual Growth (%) and CAGR (%), 2011-2014
  • Table 5.23: Gardasil Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
  • Table 5.24: Zytiga Revenue ($bn), Annual Growth (%) and CAGR (%), 2011-2014
  • Table 5.25: Zytiga Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
  • Table 5.26: Xeloda Revenue ($bn), Annual Growth (%) and CAGR (%), 2011-2014
  • Table 5.27: Xeloda Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
  • Table 5.28: Tarceva Revenue ($bn), Annual Growth (%) and CAGR (%), 2011-2014
  • Table 5.29: Tarceva Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
  • Table 5.30: Afinitor Revenue ($bn), Annual Growth (%) and CAGR (%), 2011-2014
  • Table 5.31: Afinitor Revenue Forecast ($bn), Annual Growth(%) and CAGR (%), 2015-2025
  • Table 5.32: Sprycel Revenue ($bn), Annual Growth (%) and CAGR (%), 2011-2014
  • Table 5.33: Sprycel Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
  • Table 5.34: Tasigna Revenue ($bn), Annual Growth (%) and CAGR (%), 2011-2014
  • Table 5.35: Tasigna Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
  • Table 5.36: Sutent Revenue ($bn), Annual Growth (%) and CAGR (%), 2011-2014
  • Table 5.37: Sutent: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
  • Table 5.38: Nexavar Revenue ($bn), Annual Growth (%) and CAGR (%), 2011-2014
  • Table 5.39: Nexavar: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
  • Table 5.40: Xgeva Revenue ($bn), Annual Growth (%) and CAGR (%), 2011-2014
  • Table 5.41: Xgeva Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
  • Table 5.42: Zoladex Revenue ($bn), Annual Growth (%) and CAGR (%), 2011-2014
  • Table 5.43: Zoladex Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
  • Table 5.44: Yervoy Revenue ($bn), Annual Growth (%) and CAGR (%), 2011-2014
  • Table 5.45: Yervoy Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
  • Table 5.46: Vidaza Revenue ($bn), Annual Growth (%) and CAGR (%), 2011-2014
  • Table 5.47: Vidaza Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
  • Table 5.48: Treanda Revenue ($bn), Annual Growth (%) and CAGR (%), 2011-2014
  • Table 5.49: Treanda Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
  • Table 5.50: Temodar Revenue ($bn), Annual Growth (%) and CAGR (%), 2011-2014
  • Table 5.51: Temodar Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
  • Table 5.52: Faslodex Revenue ($bn), Annual Growth (%) and CAGR (%), 2011-2014
  • Table 5.53: Faslodex Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
  • Table 5.54: Abraxane Revenue ($bn), Annual Growth (%) and CAGR (%), 2011-2014
  • Table 5.55: Abraxane: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
  • Table 6.1: Farydak: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
  • Table 6.2: Ibrance: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
  • Table 6.3: Lenvima: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
  • Table 6.4: Opdivo: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
  • Table 6.5: Unituxin: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
  • Table 6.6: Beleodaq: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
  • Table 6.7: Blincyto: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
  • Table 6.8: Cyramza: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
  • Table 6.9: Imbruvica: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
  • Table 6.10: Keytruda: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
  • Table 6.11: Lynparza: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
  • Table 6.12: Zydelig: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
  • Table 6.13: Zykadia: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
  • Table 6.14: Tafinlar: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
  • Table 6.15: Kadcyla: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
  • Table 7.1: Anti-Cancer Drug Revenues ($bn) and Market Shares (%) of Leading Companies, 2013-2014
  • Table 7.2: Roche - Anti-Cancer Drugs by Revenue ($bn), Change (%) and Share (%), 2014
  • Table 7.3: Roche's Anti-Cancer Drug Development Pipeline, 2014
  • Table 7.4: Novartis - Anti-Cancer Drugs by Revenue ($bn), Change (%) and Share (%), 2014
  • Table 7.5: Novartis' Anti-Cancer Drug Pipeline, 2014
  • Table 7.6: Celgene - Anti-Cancer Drugs by Revenue ($bn), Change (%) and Share (%), 2014
  • Table 7.7: Celgene's Anti-Cancer Drug Pipeline, 2014
  • Table 7.8: Eli Lilly - Anti-Cancer Drugs by Revenue ($bn), Change (%) and Share (%), 2014
  • Table 7.9: Eli Lilly's Anti-Cancer Drug Pipeline, 2014
  • Table 7.10: AstraZeneca - Anti-Cancer Drugs by Revenue ($bn), Change (%) and Share (%), 2014
  • Table 7.11: AstraZeneca's Anti-Cancer Drug Pipeline, 2014
  • Table 7.12: Bristol-Myers Squibb - Anti-Cancer Drugs by Revenue ($bn), Change (%) and Share (%), 2014
  • Table 7.13: Bristol-Myers Squibb Anti-Cancer Drug Pipeline, 2014
  • Table 7.14: Merck - Anti-Cancer Drugs by Revenue ($bn), Change (%) and Share (%), 2014
  • Table 7.15: Merck's Anti-Cancer Drug Pipeline, 2014
  • Table 7.16: J&J - Anti-Cancer Drugs by Revenue ($bn), Change (%) and Share (%), 2014
  • Table 7.17: J&J's Anti-Cancer Drug Pipeline, 2014
  • Table 8.1: Cancer Medicines in Testing: Numbers by Therapeutic Area, 2014
  • Table 8.2: Breast Cancer Drugs under Development, 2014
  • Table 8.3: Prostate Cancer Drugs under Development, 2014
  • Table 8.4: Lung Cancer Drugs under Development, 2014
  • Table 8.5: Colorectal Cancer Drugs under Development, 2014
  • Table 8.6: Cervical Cancer Drugs under Development, 2014
  • Table 8.7: Stomach Cancer Drugs under Development, 2014
  • Table 8.8: Liver Cancer Drugs under Development, 2014
  • Table 8.9: Ovarian Cancer Drugs under Development, 2014
  • Table 8.10: Bladder Cancer Drugs under Development, 2014
  • Table 8.11: Non-Hodgkin's Lymphoma Drugs under Development, 2014
  • Table 8.12: Leukaemia Drugs under Development, 2014
  • Table 8.13: Kidney Cancer Drugs under Development, 2014
  • Table 8.14: Pancreatic Cancer Drugs under Development, 2014
  • Table 9.1: Strengths, Weaknesses, Opportunities and Threats in the Anti-Cancer Drugs Market, 2015
  • Table 9.2: Social, Technological, Economic and Political Analysis of the Anti-Cancer Drugs Market, 2015

List of Figures

  • Figure 1.1: Anti-Cancer Market Segmentation, 2015
  • Figure 3.1: The Global Anti-Cancer Drugs Market: Revenue Forecast ($bn), 2015-2025
  • Figure 3.2: Global Anti-Cancer Drugs Market: Drivers and Restraints, 2015-2025
  • Figure 3.3: Global Anti-Cancer Drugs Market Share (%) by Therapeutic Area, 2014
  • Figure 3.4: Global Anti-Cancer Drugs Market Share (%) by Therapeutic Area, 2019
  • Figure 3.5: Global Anti-Cancer Drugs Market Share (%) by Therapeutic Area, 2025
  • Figure 3.6: Global Immunotherapy Market: Revenue Forecast ($bn), 2015-2025
  • Figure 3.7: Immunotherapy Market: Drivers and Restraints, 2015-2025
  • Figure 3.8: Global Chemotherapy Market: Revenue Forecast ($bn), 2015-2025
  • Figure 3.9: Chemotherapy Market: Drivers and Restraints, 2015-2025
  • Figure 3.10: Global Targeted Therapy Market: Revenue Forecast ($bn), 2015-2025
  • Figure 3.11: Targeted Therapy Market: Drivers and Restraints, 2015-2025
  • Figure 3.12: Global Hormone Therapy Market: Revenue Forecast ($bn), 2015-2025
  • Figure 3.13: Hormone Therapy Market: Drivers and Restraints, 2015-2025
  • Figure 4.1: Developed National Markets: Drivers and Restraints, 2015-2025
  • Figure 4.2: Emerging National Markets: Drivers and Restraints, 2015-2025
  • Figure 4.3: The Leading National Anti-Cancer Drugs Markets by Share of Global Market (%), 2014
  • Figure 4.4: The Leading National Anti-Cancer Drugs Markets by Share of Global Market (%), 2019
  • Figure 4.5: The Leading National Anti-Cancer Drugs Markets by Share of Global Market (%), 2025
  • Figure 4.6: The US Anti-Cancer Drugs Market Revenue Forecast ($bn), 2015-2025
  • Figure 4.7: The Japanese Anti-Cancer Drugs Market Revenue Forecast ($bn), 2015-2025
  • Figure 4.8: The EU5 Anti-Cancer Drugs Markets: Revenue Forecast ($bn), 2015-2025
  • Figure 4.9: The EU5 Countries: Shares of the Anti-Cancer Drugs Market (%), 2014
  • Figure 4.10: The EU5 Countries: Shares of the Anti-Cancer Drugs Market (%), 2019
  • Figure 4.11: The EU5 Countries: Shares of the Anti-Cancer Drugs Market (%), 2025
  • Figure 4.12: BRIC Countries Anti-Cancer Drugs Market Shares (%), 2014
  • Figure 4.13: BRIC Countries Anti-Cancer Drugs Market Shares (%), 2019
  • Figure 4.14: BRIC Countries Anti-Cancer Drugs Market Shares (%), 2025
  • Figure 4.15: Brazilian Anti-Cancer Drugs Market: Revenue Forecast ($bn), 2015-2025
  • Figure 4.16: Russian Anti-Cancer Drugs Market: Revenue Forecast ($bn), 2015-2025
  • Figure 4.17: Indian Anti-Cancer Drugs Market: Revenue Forecast ($bn), 2015-2025
  • Figure 4.18: Chinese Anti-Cancer Drugs Market: Revenue Forecast ($bn), 2015-2025
  • Figure 5.1: Top 10 Anti-Cancer Drugs: Market Share (%), 2014
  • Figure 5.2: Top 10 Anti-Cancer Drugs: Market Share (%), 2019
  • Figure 5.3: Top 10 Anti-Cancer Drugs: Market Share (%), 2025
  • Figure 5.4: Avastin Revenue ($bn), 2011-2014
  • Figure 5.5: Avastin Revenue Forecast ($bn), 2015-2025
  • Figure 5.6: Avastin: Drivers and Restraints, 2015-2025
  • Figure 5.7: Herceptin Revenue ($bn), 2011-2014
  • Figure 5.8: Herceptin Revenue Forecast ($bn), 2015-2025
  • Figure 5.9: Herceptin: Drivers and Restraints, 2015-2025
  • Figure 5.10: Rituxan/MabThera Revenue ($bn), 2011-2014
  • Figure 5.11: Rituxan/MabThera Revenue Forecast ($bn), 2015-2025
  • Figure 5.12: Rituxan/MabThera: Drivers and Restraints, 2015-2025
  • Figure 5.13: Glivec Revenue ($bn), 2011-2014
  • Figure 5.14: Glivec Revenue Forecast ($bn), 2015-2025
  • Figure 5.15: Glivec: Drivers and Restraints, 2015-2025
  • Figure 5.16: Revlimid Revenue ($bn), 2011-2014
  • Figure 5.17: Revlimid Revenue Forecast ($bn), 2015-2025
  • Figure 5.18: Revlimid: Drivers and Restraints, 2015-2025
  • Figure 5.19: Alimta Revenue ($bn), 2011-2014
  • Figure 5.20: Alimta Revenue Forecast ($bn), 2015-2025
  • Figure 5.21: Alimta: Drivers and Restraints, 2015-2025
  • Figure 5.22: Velcade Revenue ($bn), 2011-2014
  • Figure 5.23: Velcade Revenue Forecast ($bn), 2015-2025
  • Figure 5.24: Velcade: Drivers and Restraints, 2015-2025
  • Figure 5.25: Erbitux Revenue ($bn), 2011-2014
  • Figure 5.26: Erbitux Revenue Forecast ($bn), 2015-2025
  • Figure 5.27: Erbitux: Drivers and Restraints, 2015-2025
  • Figure 5.28: Gardasil Revenue ($bn), 2011-2014
  • Figure 5.29: Gardasil Revenue Forecast ($bn), 2015-2025
  • Figure 5.30: Gardasil: Drivers and Restraints, 2015-2025
  • Figure 5.31: Zytiga Revenue ($bn), 2011-2014
  • Figure 5.32: Zytiga Revenue Forecast ($bn), 2015-2025
  • Figure 5.33: Zytiga: Drivers and Restraints, 2015-2025
  • Figure 5.34: Xeloda Revenue ($bn), 2011-2014
  • Figure 5.35: Xeloda Revenue Forecast ($bn), 2015-2025
  • Figure 5.36: Xeloda: Drivers and Restraints, 2015-2025
  • Figure 5.37: Tarceva Revenue ($bn), 2011-2014
  • Figure 5.38: Tarceva: Revenue Forecast ($bn), 2015-2025
  • Figure 5.39: Tarceva: Drivers and Restraints, 2015-2025
  • Figure 5.40: Afinitor Revenue ($bn), 2011-2014
  • Figure 5.41: Afinitor Revenue Forecast ($bn), 2015-2025
  • Figure 5.42: Afinitor: Drivers and Restraints, 2015-2025
  • Figure 5.43: Sprycel Revenue ($bn), 2011-2014
  • Figure 5.44: Sprycel Revenue Forecast ($bn), 2015-2025
  • Figure 5.45: Sprycel: Drivers and Restraints, 2015-2025
  • Figure 5.46: Tasigna Revenue ($bn), 2011-2014
  • Figure 5.47: Tasigna Revenue Forecast ($bn), 2015-2025
  • Figure 5.48: Tasigna: Drivers and Restraints, 2015-2025
  • Figure 5.49: Sutent Revenue ($bn), 2011-2014
  • Figure 5.50: Sutent: Revenue Forecast ($bn), 2015-2025
  • Figure 5.51: Sutent: Drivers and Restraints, 2015-2025
  • Figure 5.52: Nexavar Revenue ($bn), 2011-2014
  • Figure 5.53: Nexavar: Revenue Forecast ($bn), 2015-2025
  • Figure 5.54: Nexavar: Drivers and Restraints, 2015-2025
  • Figure 5.55: Xgeva Revenue ($bn), 2011-2014
  • Figure 5.56: Xgeva Revenue Forecast ($bn), 2015-2025
  • Figure 5.57: Xgeva: Drivers and Restraints, 2015-2025
  • Figure 5.58: Zoladex Revenue ($bn), 2011-2014
  • Figure 5.59: Zoladex: Revenue Forecast ($bn), 2015-2025
  • Figure 5.60: Zoladex: Drivers and Restraints, 2015-2025
  • Figure 5.61: Yervoy Revenue ($bn), 2011-2014
  • Figure 5.62: Yervoy Revenue Forecast ($bn), 2015-2025
  • Figure 5.63: Yervoy: Drivers and Restraints, 2015-2025
  • Figure 5.64: Vidaza Revenue ($bn), 2011-2014
  • Figure 5.65: Vidaza: Revenue Forecast ($bn), 2015-2025
  • Figure 5.66: Vidaza: Drivers and Restraints, 2015-2025
  • Figure 5.67: Treanda Revenue ($bn), 2011-2014
  • Figure 5.68: Treanda Revenue Forecast ($bn), 2015-2025
  • Figure 5.69: Treanda: Drivers and Restraints, 2015-2025
  • Figure 5.70: Temodar Revenue ($bn), 2011-2014
  • Figure 5.71: Temodar Revenue Forecast ($bn), 2015-2025
  • Figure 5.72: Temodar: Drivers and Restraints, 2015-2025
  • Figure 5.73: Faslodex Revenue ($bn), 2011-2014
  • Figure 5.74: Faslodex Revenue Forecast ($bn), 2015-2025
  • Figure 5.75: Faslodex: Drivers and Restraints, 2015-2025
  • Figure 5.76: Abraxane Revenue ($bn), 2011-2014
  • Figure 5.77: Abraxane: Revenue Forecast ($bn), 2015-2025
  • Figure 5.78: Abraxane: Drivers and Restraints, 2015-2025
  • Figure 6.1: Farydak: Revenue Forecast ($bn), 2015-2025
  • Figure 6.2: Ibrance: Revenue Forecast ($bn), 2015-2025
  • Figure 6.3: Lenvima: Revenue Forecast ($bn), 2015-2025
  • Figure 6.4: Opdivo: Revenue Forecast ($bn), 2015-2025
  • Figure 6.5: Unituxin: Revenue Forecast ($bn), 2015-2025
  • Figure 6.6: Beleodaq: Revenue Forecast ($bn), 2015-2025
  • Figure 6.7: Blincyto: Revenue Forecast ($bn), 2015-2025
  • Figure 6.8: Cyramza: Revenue Forecast ($bn), 2015-2025
  • Figure 6.9: Imbruvica: Revenue Forecast ($bn), 2015-2025
  • Figure 6.10: Keytruda: Revenue Forecast ($bn), 2015-2025
  • Figure 6.11: Lynparza: Revenue Forecast ($bn), 2015-2025
  • Figure 6.12: Zydelig: Revenue Forecast ($bn), 2015-2025
  • Figure 6.13: Zykadia: Revenue Forecast ($bn), 2015-2025
  • Figure 6.14: Tafinlar: Revenue Forecast ($bn), 2015-2025
  • Figure 6.15: Kadcyla: Revenue Forecast ($bn), 2015-2025
  • Figure 7.1: Anti-Cancer Drug Market Share (%) by Leading Company, 2013
  • Figure 7.2: Anti-Cancer Drugs Market Share (%) by Leading Company, 2014
  • Figure 7.3: Roche's Top Selling Anti-Cancer Drugs by Share of Company Revenue (%), 2014
  • Figure 7.4: Novartis' Top Selling Anti-Cancer Drugs by Share of Company Revenue (%), 2014
  • Figure 7.5: Celgene's Top Selling Anti-Cancer Drugs by Share of Company Revenue (%), 2014
  • Figure 7.6: Eli Lilly's Top Selling Anti-Cancer Drugs by Share of Company Revenue (%), 2014
  • Figure 7.7: AstraZeneca's Top Selling Anti-Cancer Drugs by Share of Company Revenue (%), 2014
  • Figure 7.8: Bristol-Myers Squibb's Top Selling Anti-Cancer Drugs by Share of Company Revenue (%), 2014
  • Figure 7.9: Merck's Top Selling Anti-Cancer Drugs by Share of Company Revenue (%), 2014
  • Figure 7.10: J&J Top Selling Anti-Cancer Drugs by Share of Company Revenue (%), 2014
  • Figure 8.1: Cancer Medicines in Testing: Numbers by Therapeutic Area, 2014
  • Figure 11.1: Top 25 Anti-Cancer Drugs: Revenues ($bn), 2014

Companies Listed

  • AbbVie
  • Active Biotech
  • Advaxis
  • Alchemia
  • Allergan
  • American Cancer Society
  • Amgen
  • AmpImmune
  • Argos Therapeutics
  • ArQule
  • AstraZeneca
  • Barvarian Nordic
  • Bayer
  • Biothera
  • BioXpress Therapeutics
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Celator Pharmaceuticals
  • Celgene
  • Clovis Oncology
  • Cyclacel
  • Daiichi Sankyo
  • Dendreon
  • Dr. Reddy's Laboratories
  • Eisai
  • Eli Lilly
  • EMA
  • Sanofi
  • EMD Serono
  • European Commission
  • FDA
  • Galena Biopharma
  • Gilead
  • GSK
  • Heat Biologics
  • Immatics Biotechnologies
  • Infinity Pharmaceuticals
  • Inovio Pharmaceuticals
  • Janssen
  • Japanese MHLW
  • Jennerex Biotherapeutics
  • Jiangsu Hengrui Medicine
  • Johnson & Johnson
  • Massachusetts General Hospital
  • MedImmune
  • Merck & Co.
  • Merck KGaA
  • Merrimack
  • National Cancer Institute
  • National Comprehensive Cancer Network
  • Newlink
  • Novartis
  • OncoGenex
  • Onyx
  • Orion
  • OSi Pharmaceuticals
  • Petrov Institute of Oncology
  • Pfizer
  • Pharmacyclics
  • Progen Pharmaceuticals
  • Puma Biotechnology
  • Roche
  • Rose Li and Associates
  • Spectrum Pharmaceuticals
  • Spirogen
  • Sun Pharma
  • Sunesis Pharmaceuticals
  • Syndax
  • Takeda
  • Telomedix
  • TESARO
  • Teva Pharmaceuticals
  • Tracon Pharma
  • Transgene
  • United Therapeutics
  • Vaccinogen
  • Viventia Biotech
  • Xbiotech
Back to Top